Navigation Links
Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
Date:8/21/2007

s of this study suggested that maximum benefit accrued to patients whose LDH did not exceed 80% of the upper limit of normal for LDH. Efficacy results in this group of 274 patients (who are the focus of the new AGENDA trial) are displayed in the table below. The hazard ratios indicate that the addition of Genasense to DTIC was associated with a 42% reduction in the risk of disease progression and a 36% reduction in risk of death.

Endpoint Genasense/DTIC DTIC Hazard P

Ratio

Overall response 20.8% 7.2% 0.002

Durable response 10.7% 2.4% 0.007

Progression-free

survival, median 3.6 mos. 1.6 mos. 0.58 <0.0001

Overall survival,

median 12.3 mos. 9.9 mos. 0.64 0.0009

About Melanoma

Malignant melanoma is the most deadly form of skin cancer. The incidence of this disease is increasing by approximately 4% annually in the US. In 2004, the American Cancer Society estimates more than 55,000 cases of malignant melanoma will have been diagnosed. Melanoma is the number one cause of cancer death in women aged 25 to 29. More information about melanoma can be accessed at the Melanoma Research Foundation: http://www.melanoma.org. The EADO is an international cooperative group dedicated to promote, coordinate and improve clinical and laboratory research activities in skin cancer. Further information about the EADO can be viewed at: http://www.eado.org/.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. The Company's research platform is anchored by two ma
'/>"/>

SOURCE Genta Incorporated

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
2. Genta Incorporated to Present Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Malvern initiates European user group meetings for chemical imaging
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... CHICAGO, Ill. , June 1, 2015  AbbVie ... 2015 Healthcare Conference on Thursday, June 4, 2015. ... will participate in a question and answer session at ... webcast of the presentation will be accessible through AbbVie,s ... archived edition of the session will be available later ...
(Date:6/1/2015)... BOSTON , June 1, 2015 Symbiotix ... a $2.3 million Phase 2 Small Business Technology Transfer ... (NIH) National Institute of Allergy and Infectious Diseases (NIAID). ... is developing a novel class of molecular therapeutics ... lead clinical candidate, Polysaccharide A (PSA), is the first ...
(Date:6/1/2015)... N.J. , June 1, 2015  Elusys ... and Drug Administration (FDA) has accepted for filing ... Anthim® (obiltoxaximab) for the treatment and prevention of ... submitted on March 20, 2015. Anthim is a ... Stockpile, the U.S. government,s repository of critical medical ...
Breaking Medicine Technology:Symbiotix Biotherapies Announces $2.3 Million Award from NIH's National Institute of Allergy and Infectious Diseases (NIAID) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 2U.S. Food And Drug Administration Accepts Biologics License Application For Anthim (Obiltoxaximab) 3
... NEW YORK, April 18, 2012 Financial executives in ... excise tax and the burden of its related compliance ... bottom lines, according to a survey conducted by KPMG ... of respondents said their companies are already contemplating actions ...
... NEW YORK, April 18, 2012 ... initiates coverage on Pacira Pharmaceuticals ... price target $18.00. ... is a member of the ...
Cached Medicine Technology:KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 2KPMG Survey: Medical Device Execs Say New Excise Tax Will Hit Their Company Bottom Lines Hard 3
(Date:6/1/2015)... Ore. (PRWEB) June 01, 2015 ... (AHIP) announced today a new, interactive Affordable Care ... large employers. The course, called “Affordable Care Act ... professionals with the strategic and consultative insights necessary ... as they navigate the impacts of the ACA. ...
(Date:6/1/2015)... a leading web-base electronic healthcare software (EHR) is providing ... Louisiana. The entrepreneurial trio behind Sharenote, will travel to ... with the tools and resources to monitor key performance ... , Find out why Sharenote is the EHR ... 250 practices. , Four Day Schedule , ...
(Date:6/1/2015)... 2015 KC and Monica Craichy, Founders ... the best superfood products in the world ... Texas. , "Monica and I are excited to ... distributing Living Fuel Super Meals - SuperBerry®, SuperGreens and ... in Texas," KC Craichy said. "We have attempted to ...
(Date:6/1/2015)... (PRWEB) June 01, 2015 More than 22 ... summer months when school is out and they lose access ... Month and America’s dairy farmers and milk companies are on ... need with The Great American Milk Drive. , In ... provided in the school cafeteria for the bulk of their ...
(Date:6/1/2015)... Northridge dentist , Dr. Michel Elyson, ... promotion on Invisalign for a limited time only. With ... to $3,700. Patients can find out about their candidacy ... the extent of correction they need. This promotion expires ... any other offer. , Invisalign has continued to ...
Breaking Medicine News(10 mins):Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 2Health News:Cambia Partners with AHIP to Offer Expert Series ACA Training Course 3Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 2Health News:Nearly $100,000 In Emergency Food Aid to Flood Victims in Texas Provided by Living Fuel and Natural News 3Health News:Summer Nutrition Vital for Kids who Depend on Schools for Healthy Foods 2Health News:Northridge Dentists, Drs. Michel Elyson and Ramin Assili, are Now Offering a Limited Time Promotion on Invisalign 2
... menstrual cycle into account when booking exam may cut need ... News) -- Using a blood test to pinpoint the optimal ... cycles could reduce the need for repeat scans, U.S. researchers ... scans during the follicular phase (days 3 to14) of the ...
... of successful events organised last year, a second Joint ... (ESC) and the European Association for the Study of ... organisations in Europe, will be held from 27-29 November ... Guangzhou. The theme is the Optimal Management of Diabetes, ...
... YORK, Nov. 20 Mallika Chopra, healthy living expert and ... natural stress relief products in the US, are teaming up ... program kicks off with advice from Chopra, to be posted ... the holidays without the stress or foreboding that typically comes ...
... and palliation in patients with pancreatic neuroendocrine tumors (PNTs), ... therapy, according to a largest of its kind study ... Journal of Radiation Oncology*Biology*Physics , the official journal of ... is a very rare form of pancreatic cancer that ...
... every 2 years or more, not annually, , FRIDAY, Nov. ... week, medical experts are revising the advice given women on ... should get their first screening for cervical cancer -- including ... in guidelines released Nov. 20 by the American College of ...
... 20 New data released today by Quest ... provider of employment-related drug testing services, reveal that drug testing ... general U.S. workforce has tracked sharp downward trends in cocaine ... 2009 that mirror similar drops shown by urine testing. Data ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:ESC to give talks on diabetes in 3 cities in China 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 2Health News:Survive and Thrive This Holiday Season with Rescue Remedy and Advice from Mallika Chopra 3Health News:Rare pancreatic cancer patients may live longer when treated with radiation therapy 2Health News:New Pap Test Guidelines: Start Later, Have Fewer 2Health News:New Pap Test Guidelines: Start Later, Have Fewer 3Health News:New Pap Test Guidelines: Start Later, Have Fewer 4Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 2Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 3Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 4Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 5Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 6Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 7Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 8Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 9Health News:New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM) 10
The ARC Laser MISC combines a pharo unit + Lyla laser module = Photolysis....
... Detect™ IgM Capture ELISA is for the ... WNV recombinant antigens (WNRA) in serum as ... of West Nile virus infection in patients ... results must be confirmed by Plaque Reduction ...
Adult; dilates 6.0 to 34.0 French; individually packaged, sterile....
The removable inflation adapter allows the ureteroscope to be removed after the catheter is in place. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: